CSE Bulletin: Consolidation - Mydecine Innovations Group Inc.

CSE Bulletin: Consolidation - Mydecine Innovations Group Inc.

MYDECINE INNOVATIONS GROUP INC. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every fifty (50) pre-consolidated common shares.

As a result, the number of outstanding shares will be reduced to approximately 1,235,107 common shares.

The name and symbol will not change.

Please note that all open orders will be canceled at the close of business on October 20, 2025. Dealers are reminded to re-enter their orders taking into account the share consolidation.

_________________________________

MYDECINE INNOVATIONS GROUP INC. a annoncé une consolidation de ses actions ordinaires émises et en circulation sur la base d'une (1) action ordinaire post-consolidée pour chaque cinquante (50) actions ordinaires pré-consolidées.

En conséquence, le nombre d'actions en circulation sera réduit à environ 1 235 107 actions ordinaires.

Le nom et le symbole ne changeront pas.

Veuillez noter que toutes les commandes ouvertes seront annulées à la fermeture des bureaux le 20 octobre 2025. Les négociants sont invités à ressaisir leurs commandes en tenant compte de la consolidation des actions.

Trading on a Consolidated Basis/Négociation sur une Base Consolidée : Le 21 OCT 2025
Record Date/Date d'Enregistrement : Le 21 OCT 2025
Anticipated Payment Date/Date de Paiement Prévue : Le 21 OCT 2025
Symbol/Symbole : MYCO
NEW/NOUVEAU CUSIP : 62849F 40 8
NEW/NOUVEAU ISIN : CA62849F 40 8 7
Old/Vieux CUSIP & ISIN : 62849F200/CA62849F2008

 

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com.

Pour toute question ou information complémentaire, veuillez contacter Listings au 416 367-7340 ou par courriel à: Listings@thecse.com.

News Provided by Newsfile via QuoteMedia

MYCO:CC
The Conversation (0)
Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues

Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues

MYDECINE INNOVATIONS GROUP INC. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is glad to... Keep Reading...
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

MYDECINE INNOVATIONS GROUP INC. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to... Keep Reading...

Interactive Chart

Latest Press Releases

Related News